All News

SI.Sacroiliitis.AS_.jpg

ASLeap: Higher Dose Secukinumab in Ankylosing Spondylitis

Jack Cush, MD

Ankylosing spondylitis (AS) patients not responding to usual dosing with secukinumab (150 mg) after 16 weeks were dose escalated to secukinumab (SEC) 300 mg, but failed to show improvement by week 52.

Read Article
CV,risk,MI,heart,cardiac

Less Mortality with GLP-1 Agonists in Rheumatic Patients

Jack Cush, MD

A recent article in PLOS ONE has shown that treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists (GLP-1-RAs) was associated with a significant lowering of risk of all-cause mortality and major adverse cardiovascular events in patients with immune-mediated inflammatory diseases and type 2 diabetes.

Read Article
RheumNow Podcast square

Depends on Where You’re Looking (8.9.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week.

Read Article
back, LBP, spine, AS

Finding Spondylitis Among Psoriasis, Uveitis and Colitis Patients

Jack Cush, MD

Maksymowych and colleagues have shown that screening patients with either psoriasis, iritis, or colitis may yield a surprising percentage meeting ASAS criterial for axial spondyloarthritis (axSpA).

Read Article
LBP.Child.juvenile.SpA

New Classification Criteria for Juvenile Axial Spondyloarthritis

Jack Cush, MD

An expert panel has published new and validated classification criteria for axial disease in children with juvenile spondyloarthritis (SpA; AxJSpA).

Read Article
RheumNow Podcast square

Pollution and Autoimmunity (7.12.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
Dead Words Eulogy Cover Image

ICYMI: Dead Words Eulogy

Jack Cush, MD

The trouble with rheumatology may be the words we live by. Welcome to the eulogy for rheumatology 'dead words'. We're here today to celebrate the loss of rheumatology past. These are dead words in rheumatology, words fortified unfortunately by history and habit. The lexicon of rheumatology is unique, it's challenging and it's mostly incomprehensible to those who don't know...but those are the cornerstones of the greatest of medical subspecialties. 

Read Article
Depends on Where You’re Looking (8.9.2024) https://t.co/GDAN37DJSx https://t.co/jVoumC00r5

Links:

Dr. John Cush RheumNow ( View Tweet)
Full Read Overview of the safety of bDMARDs/tsDMARDS - contraindications, precautions, & boxed warnings for treatment of RA, PsA, SpA, JIA - safety checklist for a class of drugs you use and diseases you treat https://t.co/5chrS3sW8i https://t.co/twSv4Zs9r3

Links:

Dr. John Cush RheumNow ( View Tweet)
Finding Spondylitis Among Psoriasis, Uveitis and Colitis Patients Maksymowych and colleagues have shown that screening patients with either psoriasis, iritis, or colitis may yield a surprising percentage meeting ASAS criterial for axSpA. https://t.co/lVCdGnMVaT https://t.co/jFILeHrQXj

Links:

Dr. John Cush RheumNow ( View Tweet)
Pt Reported Outcomes in axSpA or PsA may be interpreted differently if fibromyalgia is present. ASDAS-CRP, & duration of lumbar AM stiffness were not affected by FM, yet FM significantly caused higher scores in axSpA or PsA all assessments https://t.co/v8wFzIVxUr https://t.co/eIXRoktYja

Links:

Dr. John Cush RheumNow ( View Tweet)
Full Read Overview of the safety of bDMARDs/tsDMARDS - contraindications, precautions, & boxed warnings for treatment of RA, PsA, SpA, JIA - safety checklist for a class of drugs you use and diseases you treat https://t.co/TIdCtJjF21 https://t.co/UE0nGbESDB

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 136 referred LBP pts (71 w/ DDD, 38 DISH, 27 axSpA) found significant overlap of imaging features in all 3. SpA-like spine CR features were found in 1/4 of patients with DISH, and MRI BM edema found in 1/3 of those patients. https://t.co/dKIcuE3IGZ https://t.co/OITtOKEuNC

Links:

Dr. John Cush RheumNow ( View Tweet)
New Classification Criteria for Juvenile Axial Spondyloarthritis An expert panel has published new and validated classification criteria for axial disease in children with juvenile spondyloarthritis (SpA; AxJSpA). https://t.co/kxtHlEk5XG https://t.co/jKAp9W5Di1

Links:

Dr. John Cush RheumNow ( View Tweet)
Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria. https://t.co/ZR5pFINagR https://t.co/bEWjSXWlB0

Links:

Dr. John Cush RheumNow ( View Tweet)
UK study of pneumococcal vaccination in UK, shows IMID pts had suboptimal vax against pneumococcus. In 32 277 pts (RA 14151, IBD 13631, SpA 3804, SLE 691) saw 57% vaccinated; lower if <45 yrs (32%), IBD (42%). Vax not associated w/ IMID flare https://t.co/y5JHYaEpA9 https://t.co/zUXfDoqyal

Links:

Dr. John Cush RheumNow ( View Tweet)
Bimekizumab (dual-IL-17A/F inhib), may prevent uveitis in patients with axSpA. In phase 3 RCTs (MOBILE 1 & 2) double-blind period, uveitis seen in 0.6% on BKZ vs 4.6% on PBO (p=0.001). In pts w/ hx uveitis, again lower w/ BKZ (6.2/100 PYs vs 70.4/100 PYs) https://t.co/v0wMK45chz https://t.co/CVPdg1k41V

Links:

Dr. John Cush RheumNow ( View Tweet)
Paradoxical psoriasis w/ IL-17 inhib? Lit review 35 (SpA) pts, presenting as palmoplantar pustular and plaque PsO; median 11 weeks after IL-17i. one-third continued IL-17i w/ mostly topical Rx; 2/3 D/C IL-17i, switching to other biologic w/ good outcomes https://t.co/q2xqQyiM3b https://t.co/6hSE6NLHWw

Links:

Dr. John Cush RheumNow ( View Tweet)
10 baseline predictors for achieving treatment response to Secukinumab in the EuroSpA study. Having non-radiographic disease was a negative predictor of obtaining LDA at 6 months and remaining on treatment at 12 months in European axSpA patients initiating secukinumab. #EULAR2024

Dr. John Cush RheumNow ( View Tweet)

Imaging in Axial Spondyloarthritis Dr. Antoni Chan reviews abstracts OP0222 and OP0303 presented at Eular 2024 in Vienna, Austria. https://t.co/SqTi4Xvoo2 https://t.co/TzZdUEkOXW

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×